AU2006279633B2 - Human monoclonal antibodies that specifically bind IGF-II - Google Patents

Human monoclonal antibodies that specifically bind IGF-II Download PDF

Info

Publication number
AU2006279633B2
AU2006279633B2 AU2006279633A AU2006279633A AU2006279633B2 AU 2006279633 B2 AU2006279633 B2 AU 2006279633B2 AU 2006279633 A AU2006279633 A AU 2006279633A AU 2006279633 A AU2006279633 A AU 2006279633A AU 2006279633 B2 AU2006279633 B2 AU 2006279633B2
Authority
AU
Australia
Prior art keywords
cancer
antibody
seq
igf
amino acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2006279633A
Other languages
English (en)
Other versions
AU2006279633A1 (en
Inventor
Dimiter S. Dimitrov
Yang Feng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2006279633A1 publication Critical patent/AU2006279633A1/en
Application granted granted Critical
Publication of AU2006279633B2 publication Critical patent/AU2006279633B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2006279633A 2005-08-17 2006-08-15 Human monoclonal antibodies that specifically bind IGF-II Ceased AU2006279633B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US70922605P 2005-08-17 2005-08-17
US60/709,226 2005-08-17
US79881706P 2006-05-08 2006-05-08
US60/798,817 2006-05-08
PCT/US2006/031814 WO2007022172A1 (en) 2005-08-17 2006-08-15 Human monoclonal antibodies that specifically bind igf-ii

Publications (2)

Publication Number Publication Date
AU2006279633A1 AU2006279633A1 (en) 2007-02-22
AU2006279633B2 true AU2006279633B2 (en) 2011-03-03

Family

ID=37564252

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006279633A Ceased AU2006279633B2 (en) 2005-08-17 2006-08-15 Human monoclonal antibodies that specifically bind IGF-II

Country Status (7)

Country Link
US (1) US8105598B2 (enExample)
EP (1) EP1924604B1 (enExample)
JP (1) JP5149800B2 (enExample)
AT (1) ATE535546T1 (enExample)
AU (1) AU2006279633B2 (enExample)
CA (1) CA2618920C (enExample)
WO (1) WO2007022172A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG179291A1 (en) 2003-06-18 2012-04-27 Genelux Corp Modified recombinant vaccinia viruses and other microorganisms, uses thereof
US7939637B2 (en) 2005-12-13 2011-05-10 Medimmune Limited Insulin-like growth factor antibodies and uses thereof
WO2009137758A2 (en) 2008-05-09 2009-11-12 Dyax Corp. Igf-ii/gf-iie binding proteins
WO2010045315A1 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
CZ2008697A3 (cs) * 2008-11-03 2010-04-28 Univerzita Karlova v Praze, 1. Lékarská fakulta Kombinace monoklonálních protilátek nebo jejich Fab fragmentu pro použití jako lécivo a farmaceutický prípravek tyto protilátky nebo jejich Fab fragmenty obsahující
US9150644B2 (en) 2011-04-12 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
US9127056B2 (en) 2011-10-17 2015-09-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
US9546219B2 (en) 2012-02-08 2017-01-17 North Carolina State University Treatment of allergic diseases with recombinant antibodies
CN106519024A (zh) * 2015-09-15 2017-03-22 三生国健药业（上海）股份有限公司 一种用于去除单克隆抗体中异构体的复性液及复性方法
EP3538558A4 (en) 2016-11-09 2020-07-15 North Carolina State University TREATMENT OF ALLERGIC DISEASES USING CHIMERIC PROTEIN
WO2019183437A1 (en) 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for antibody to high affinity receptor for ige

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MIYAMOTO, S. et al "Blockade of paracrine supply of insulin-like growth factors using neutralizing antibodies suppresses the liver metastasis of human colorectal cancers." CLINICAL CANCER RESEARCH. 2005, vol. 11, no. 9, pages 3494-3502, *
SINGH, P. et al Endocrinology. 1996 Vol. 137, no. 5, pages 1764-1774 *

Also Published As

Publication number Publication date
CA2618920A1 (en) 2007-02-22
EP1924604B1 (en) 2011-11-30
US8105598B2 (en) 2012-01-31
JP5149800B2 (ja) 2013-02-20
JP2009507471A (ja) 2009-02-26
CA2618920C (en) 2015-03-24
EP1924604A1 (en) 2008-05-28
WO2007022172A1 (en) 2007-02-22
US20110008358A1 (en) 2011-01-13
ATE535546T1 (de) 2011-12-15
AU2006279633A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
US8105598B2 (en) Human monoclonal antibodies that specifically bind IGF-II
US8357783B2 (en) Human anti-mesothelin monoclonal antibodies
EP2582727B1 (en) Antibodies to endoplasmin and their use
US9676846B2 (en) Human monoclonal antibodies that bind insulin-like growth factor (IGF) I and II
JP2013538042A5 (enExample)
JP5836125B2 (ja) 高分子量メラノーマ関連抗原に対する完全ヒト抗体およびその使用
CN106999578B (zh) 针对epha4的人类单克隆抗体和其用途
US7824681B2 (en) Human monoclonal antibodies that specifically bind IGF-II
US9127056B2 (en) Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor II (IGF-II)
AU2009305715B8 (en) Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
HK1234759A1 (en) Antibodies to endoplasmin and their use
HK1234759B (en) Antibodies to endoplasmin and their use
HK1184468B (en) Antibodies to endoplasmin and their use
HK1184468A (en) Antibodies to endoplasmin and their use
HK1235692B (zh) 针对epha4的人类单克隆抗体和其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired